Immunocon
This article was originally published in The Gray Sheet
Executive Summary
Commences pilot clinical study of its in vitro tumor cell analysis technology for the detection of breast cancer following Institutional Review Board approval Aug. 19. The study, which is targeted to enroll up to 40 participants, will attempt to detect cancer cells which shed from malignant solid tumors in the patient's blood. While the data are expected to be applied to future clinical trials, an investigational device exemption was not necessary to begin the trial as data are not expected to be used in making treatment decisions